Liver fibrosis traditionally required biopsy for accurate staging, which carries risks and samples only a small portion of liver. Multi-marker blood tests like FibroACT use algorithms combining several lab values to estimate fibrosis non-invasively.
This test is used to assess fibrosis in patients with chronic liver disease — including hepatitis C, hepatitis B, fatty liver disease, and alcohol-related liver disease — and to monitor changes over time. Results help guide treatment decisions and surveillance intensity. Sample type is serum.
We are CLIA certified, the highest level of Medical industry compliance and standards.
Book an appointment